Genmab — December 2024
-
Jeg bliver altid så glad, når jeg læser dine indlæg Riis. Det minder mig om, at Proinvestor har plads til alle.
-
Genmab
@Genmab
We are presenting new clinical data at #ASH24 across subtypes of non-Hodgkin’s lymphoma (#NHL), a type of cancer that affects the lymphatic system, usually found in the lymph nodes. Swipe to learn more about this disease and how it can affect patients.
https://x.com/Genmab/status/1865097213652668441 -
-
Investigational Epcoritamab (DuoBody
CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL). https://ir.genmab.com/news-releases/news-release-details/investigational-epcoritamab-duobodyr-cd3xcd20-combination https://ir.genmab.com/news-releases/news-release-details/investigational-epcoritamab-duobodyr-cd3xcd20-combination -
-
slides-
Fernando Martín Moro
@Fer_martinmoro
Fixed-Duration Epcoritamab + R2 in R/R Follicular Lymphoma: 2-Year Follow-up from Arm 2 Epcore NHL-2 Trial https://x.com/Fer_martinmoro/status/1865569927740203505 -
The Fixed duration regime is offcourse a response to glofitamab competition- this poster suggests it may be better to keep treating to progression (for some patients?)
https://x.com/DrRaulCordoba/status/1865654728618852709 @DrRaulCordoba
#ASH24 Interesting study
: “Treatment to progression vs FDT efficacy of #epcoritamab: a modeling and simulation study” -
"In the event of febrile neutropenia,
patients should be evaluated for infection and managed with antibiotics, fluids and other supportive care,
according to local guidelines." "Of the 105
patients who had neutropenia/neutrophil count decreased events, 61% received G-CSF to treat the
events" https://www.ema.europa.eu/en/documents/product-information/tepkinly-epar-product-information_en.pdf -
by chance this article today, shows- There are limited data on the use of G-CSF in anti-CD20 BsAbs. In a study of mosunetuzumab for R/R B-NHL, a total of 60/218 (27.5%) patients experienced a neutropenic event, and 41/60 patients (68.3%) received G-CSF, with a positive response in 39/41 patients (95.1%). A phase I trial of glofitamab noted that G-CSF was administered in 37 patients (21.6%), while a dose-expansion phase I/II study of epcoritamab noted that only 10.1% of patients required G-CSF
-
-
-
Onsdag d. 11. december......
Genmab vil holde sin Forsknings- og Udviklingsopdatering og gennemgang af de data, der præsenteres i forbindelse med for American Society of Hematology, ASH’s, årlige møde. Begivenheden, der løber af stablen onsdag klokken 17, har ikke noget med det generelle program at gøre.
nvidia har vækst;-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind